Drug Trial Radar · NCT02539134
TAK-935 Multiple Rising Dose Study in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 2015
Primary completion
Apr 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 2, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of multiple rising doses of TAK-935 in healthy participants.
Conditions
- Epilepsy
Interventions
TAK-935Drug
TAK-935 oral solution
PlaceboDrug
TAK-935 placebo-matching oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE)Time frame: Day 1 up to Day 28
- Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post DoseTime frame: Baseline up to Day 15
- Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post DoseTime frame: Baseline up to Day 15
- Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post DoseTime frame: Baseline up to Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.